Clinical trials: PALS
Papillon-Lefevre Disease
Cytokines in Papillon-Lefèvre Syndrome
Papillon-Lefèvre syndrome (PLS) is characterised by aggressively progressive periodontitis combined with palmo-plantar hyperkeratosis. It is caused by "loss of function" mutations in the cathepsin C gene.
- Trial name
- NCT01116934
- Where
- Germany
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Goethe University
Physical Activity, Weight
Physical Activity and Leisure-time Study (PALS)
Physical inactivity is a major public health problem and a primary contributing factor to the obesity epidemic. While most Americans do not meet the physical activity (PA) guidelines (30 min/day, 5 day/wk), they do report…
- Trial name
- PALS (NCT01342471)
- Testing
- TV commercial stepping, 30-min walk
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Tennessee
ALS
A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)
The causes of ALS are largely unknown. However, mitochondrial dysfunction, resulting in impaired energy production, oxidative stress and apoptosis, may play a key role in ALS progression.
- Trial name
- NCT03506425
- Testing
- Triheptanoin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Richard Bedlack, M.D., Ph.D.